Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases Earnings Results, Misses Estimates By $0.13 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued its earnings results on Tuesday. The specialty pharmaceutical company reported $5.70 earnings per share for the quarter, missing the consensus estimate of $5.83 by ($0.13), Zacks reports. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals updated its FY 2025 guidance to 22.500-24.000 EPS and its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ JAZZ traded up $2.98 during trading hours on Tuesday, hitting $139.67. 1,269,835 shares of the company traded hands, compared to its average volume of 640,889. The company’s 50 day moving average price is $125.08 and its 200 day moving average price is $118.24. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $140.52. The stock has a market capitalization of $8.44 billion, a price-to-earnings ratio of 19.67, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Analyst Ratings Changes

Several analysts recently issued reports on JAZZ shares. TD Cowen cut their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $140.00 to $175.00 in a report on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Piper Sandler restated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average price target of $180.33.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 5,053 shares of company stock worth $617,442 over the last three months. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.